HB 1239Session 114
Opioids - As enacted, clarifies that a physician licensed in this state is the only healthcare provider authorized to prescribe a buprenorphine product for a FDA-approved use in recovery or medication-assisted treatment; revises criteria for providers not licensed in this state to prescribe a buprenorphine product for the treatment of opioid use disorder. - Amends TCA Title 33; Title 41; Title 53 and Title 63.
Progress
- Introduced
- In committee
- Passed Senate
- Passed legislature
- Sent to governor
- Became law
What this bill would cost
Fiscal notes are prepared by the state’s budget staff and reflect the bill as written at the time.
Legislative history
-
House
Pub. Ch. 295
-
House
Effective date(s) 07/01/2025
-
House
Signed by Governor.
-
House
Transmitted to Governor for his action.
-
Senate
Signed by Senate Speaker
-
House
Signed by H. Speaker
-
House
Enrolled; ready for sig. of H. Speaker.
-
House
H. adopted am. (Amendment 1 - HA0252)
-
House
Sponsor(s) Added.
-
House
Passed H., as am., Ayes 92, Nays 1, PNV 0
-
House
Engrossed; ready for transmission to Sen.
-
Senate
Received from House, Passed on First Consideration
-
Senate
Senate substituted House Bill for companion Senate Bill.
-
Senate
Amendment withdrawn. (Amendment 1 - SA0095)
-
Senate
Passed Senate, Ayes 27, Nays 4
-
House
H. Placed on Regular Calendar for 4/7/2025
-
House
Placed on cal. Calendar & Rules Committee for 4/3/2025
-
House
Rec. for pass. if am., ref. to Calendar & Rules Committee
-
House
Placed on cal. Health Committee for 4/1/2025
-
House
Action def. in Health Committee to 4/1/2025
-
House
Rec for pass if am by s/c ref. to Health Committee
-
House
Placed on cal. Health Committee for 3/25/2025
-
House
Placed on s/c cal Health Subcommittee for 3/19/2025
-
House
P2C, ref. to Health Committee
-
House
Assigned to s/c Health Subcommittee
-
House
Intro., P1C.
-
House
Filed for introduction